Breaking News Instant updates and real-time market news.

JD

JD.com

$45.64

1.97 (4.51%)

, CELG

Celgene

$104.99

-1.69 (-1.58%)

07:35
01/08/18
01/08
07:35
01/08/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in JD.com (JD), Celgene (CELG), Morgan Stanley (MS), Merck (MRK), AK Steel (AKS), Fedex (FDX), Constellation Brands (STZ), Kinder Morgan (KMI), Deutsche Bank (DB), and Williams (WMB).

JD

JD.com

$45.64

1.97 (4.51%)

CELG

Celgene

$104.99

-1.69 (-1.58%)

MS

Morgan Stanley

$53.11

-0.02 (-0.04%)

MRK

Merck

$56.99

-0.06 (-0.11%)

AKS

AK Steel

$6.61

0.06 (0.92%)

FDX

FedEx

$265.92

1.04 (0.39%)

STZ

Constellation Brands, also tag STZ.B

$219.88

-5.91 (-2.62%)

KMI

Kinder Morgan

$18.95

-0.06 (-0.32%)

DB

Deutsche Bank

$18.55

-1.22 (-6.17%)

WMB

Williams

$32.46

-0.09 (-0.28%)

  • 08

    Jan

  • 08

    Jan

  • 10

    Jan

  • 10

    Jan

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 30

    Jan

  • 02

    Feb

  • 08

    Feb

  • 16

    Feb

  • 20

    Mar

  • 25

    Mar

  • 03

    Apr

JD JD.com
$45.64

1.97 (4.51%)

11/14/17
MSCO
11/14/17
DOWNGRADE
MSCO
Equal Weight
JD.com downgraded to Equal Weight from Overweight at Morgan Stanley
12/13/17
STFL
12/13/17
INITIATION
Target $48
STFL
Buy
JD.com resumed with a Buy at Stifel
Stifel analyst Scott Devitt resumed coverage of JD.com (JD) with a Buy rating and a $48 price target, saying he views the company and Alibaba (BABA) as well-managed and well-positioned leaders in China that "have effectively shut Amazon out" of the e-commerce market in the region. Devitt predicts JD should triple its 2013 market share to about 18% share by year-end and that third-party can exceed 50% of JD's gross merchandise volume within the next several years.
11/14/17
11/14/17
DOWNGRADE
Target $45

Equal Weight
JD.com downgraded to Equal Weight with pause in rally expected at Morgan Stanley
As previously reported, Morgan Stanley analyst Grace Chen downgraded JD.com to Equal Weight from Overweight following the stock's 63% year-to-date advance, as she believes headwinds from the apparel segment may temper gross merchandise value growth in the next few quarters and prompt a "breather" in the stock's rally. While she remains positive on JD's long-term growth potential, she recommends investors wait for a better entry point. Chen lowered her price target on JD shares to $45 from $53.
11/28/17
BERN
11/28/17
NO CHANGE
BERN
Grocery sales on Alibaba, JD.com are nine times Amazon's, says Bernstein
Bernstein analyst Bruno Monteyne notes that absolute grocery sales on Alibaba (BABA) and JD.com (JD) are nine times the grocery sales on Amazon.com (AMZN). China's speed is explained by a lack of legacy, as the country never developed big-box retailing, he adds. Further, Monteyne points out that Alibaba's approach has led to an asset light form of e-grocery, contrasting with the very asset-heavy approach taken by Amazon.
CELG Celgene
$104.99

-1.69 (-1.58%)

12/29/17
PIPR
12/29/17
NO CHANGE
PIPR
Biotech fund outflows continue, says Piper Jaffray
For the weekly period ending Wednesday, December 27, healthcare/biotech funds saw $338M in net outflows, representing a 0.58% decrease in assets, Piper Jaffray analyst Christopher Raymond tells investors in a research note. This marks the seventh straight negative week and the eleventh week of outflows in the past 12 weeks, the analyst points out in a research note titled "Ending 2017 on a Down Note: Biotech Outflows Continue."
01/03/18
WELS
01/03/18
UPGRADE
Target $53
WELS
Outperform
Arena Pharmaceuticals upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Arena Pharmaceuticals (ARNA) to Outperform and raised his price target for the shares to $53 from $19. The stock closed yesterday up 7% to $36.21. An improved FDA environment could facilitate approval of ralinepag in pulmonary arterial hypertension, Birchenough tells investors in a research note. He's upgrading the shares ahead of the Phase 2 data for S1P modulator etrasimod in ulcerative colitis. The analyst believes recent data from Celgene's (CELG) competing S1P modulator ozanimod "lowers the bar for differentiation." Both of Arena's assets "could attract large Pharma interest," Birchenough adds.
01/05/18
BOFA
01/05/18
DOWNGRADE
BOFA
Neutral
Celgene downgraded to Neutral from Buy at BofA/Merrill
01/05/18
BOFA
01/05/18
DOWNGRADE
BOFA
Neutral
Celgene downgraded to Neutral due to limited growth at BofA/Merrill
BofA/Merrill analyst Ying Huang upgraded Neutral from Buy and lowered its price target to $120 from $129 due to lack of catalysts, headwinds from Revlimid competition, and reduced product sales expectations.
MS Morgan Stanley
$53.11

-0.02 (-0.04%)

12/12/17
KBWI
12/12/17
UPGRADE
Target $59
KBWI
Outperform
Morgan Stanley upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded Morgan Stanley to Outperform and raised his price target for the shares to $59 from $52.
10/18/17
BMOC
10/18/17
NO CHANGE
Target $69
BMOC
Outperform
Morgan Stanley price target raised to $69 from $61 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Morgan Stanley to $69 after a Q3 top-line beat, saying the stock remains his top pick among the big six U.S. banks. Fotheringham is also raising his EPS forecast for FY17 to $3.54 from $3.41 to account for higher than previously modeled asset management fees, advisory fees, and equities trading revenues while maintaining an Outperform rating.
12/20/17
WELS
12/20/17
NO CHANGE
Target $55
WELS
Market Perform
Morgan Stanley price target raised to $55 from $48 at Wells Fargo
Wells Fargo analyst Mike Mayo raised his price target for Morgan Stanley to $55 from $48 to reflect more potential upside from a portion of higher interest rates, lower taxes, and lower cost of capital due to greater resiliency. The analyst reiterates a Market Perform rating on the shares.
10/09/17
10/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Larry Biegelsen saying J&J is poised to reaccelerate its sales growth due to accretion from the Actelion acquisition, a "more measured" than expected impact from biosimilar competition, "solid performance" of key drugs and a pipeline that is "coming to fruition." 2. Morgan Stanley (MS) upgraded to Outperform from Neutral at Credit Suisse with analyst Susan Roth Katzke citing the over 10% total return potential in the shares. 3. Disney (DIS) upgraded to Top Pick from Outperform at RBC Capital with analyst Steven Cahall saying he thinks the company has reached a turning point with ESPN approaching less than 20% of earnings and "non-Media" Disney remaining a global leader in content that is executing well. 4. INC Research (INCR) upgraded to Buy from Hold at Jefferies analyst David Windley saying the recent share pullback provides a "compelling" entry point. 5. British American Tobacco (BTI) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$56.99

-0.06 (-0.11%)

11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/24/17
DBAB
11/24/17
NO CHANGE
Target $59
DBAB
Hold
Deutsche cuts Merck target to $59 on competition from AbbVie, GSK
Deutsche Bank analyst Gregg Gilbert lowered his price target for Merck (MRK) to $59 from $62 citing expectations for more competitive pressure on Zepatier and Zostavax. The stock closed Wednesday up 10c to $54.37. Demand trends for Merck's hepatitis C virus drug Zepatier have continued to decline as AbbVie's (ABBV) Mavyret has gained traction, Gilbert told investors in a research note. The analyst also assumes "significant pressure" on Merck's shingles vaccine Zostavax from the near-term competitive launch of GlaxoSmithKline's (GSK) Shingrix. Gilbert views Merck's risk/reward as fairly balanced and he keeps a Neutral rating on the shares.
11/28/17
BOFA
11/28/17
INITIATION
Target $64
BOFA
Buy
Merck reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry reinstated coverage on Merck with a Buy and $64 price target citing attractive valuation, diversified revenue streams, pipeline potential, and a history of returning cash.
12/07/17
PIPR
12/07/17
NO CHANGE
PIPR
Roche lung cancer data underwhelming versus Merck's, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss says that while Roche's (RHHBY) IMpower150 data are strong and suggesting a likelihood that the combination of Tecentriq with Avastin and chemo will be approved in non-small cell lung cancer, the data also appear underwhelming compared to Merck's (MRK) KN-21G trial data. The analyst does expect Tecentriq approval in lung cancer next year and reiterates an Overweight rating on Roche. Whether KN-021G represents the "high water mark" for efficacy can only be answered following full presentation of the remaining pivotal Phase 3 trials in this setting, and until then confusion is likely to remain, Purkiss tells investors in a research note. Merck in premarket trading is up 85c to $55.20 while Roche is down 93c to $30.40.
AKS AK Steel
$6.61

0.06 (0.92%)

12/07/17
12/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AK Steel (AKS) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Gambardella saying the Department of Commerce's ruling against China redirecting steel to Vietnam will push steel prices higher in the U.S. 2. Shake Shack (SHAK) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst John Glass noting that the company has lifted its unit openings forecast in each of the last three years and is now growing company units at nearly 40%, which he points out is the fastest in the restaurant sector. 3. Hyatt (H) upgraded to Buy from Neutral at MKM Partners with analyst Christopher Agnew saying that GDP growth and leading economic indicators all point to stronger corporate activity in 2018, even as hotels are at record occupancy levels and supply growth is plateauing. 4. lululemon (LULU) upgraded to Hold from Sell at Canaccord with analyst Camilo Lyon saying his Sell thesis was predicated on a surging denim cycle that would take share from the athleisure wear cycle. 5. Wells Fargo (WFC) upgraded to Buy from Sell at Vertical Group. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/17
12/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Continental (UAL) upgraded to Buy from Neutral at Buckingham with the firm citing the active steps the company is taking to address revenue weakness, its commercial initiatives, a favorable macro backdrop that is driving booking strength, and the longer term cash implications of tax reform. 2. Wendy's (WEN) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan citing "solid" same-store sales growth and visibility into free cash flow generation. 3. Biogen (BIIB) upgraded to Outperform from Neutral at Credit Suisse with analyst Alethia Young saying a "significant turnaround" is underway for Biogen's business. 4. Steel Dynamics (STLD) was upgraded to Buy from Neutral at Longbow while, U.S. Steel (X), AK Steel (AKS), and Nucor (NUE) were upgraded to Buy from Neutral. 5. Zimmer Biomet (ZBH) upgraded to Neutral from Sell at Goldman Sachs with analyst Isaac Ro saying he sees Bryan Hanson's CEO appointment as a positive step forward in the turnaround process, although he noted that the company's fundamentals are still challenged and the turnaround will take time. Shares were also upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/17
LBOW
12/20/17
UPGRADE
LBOW
Buy
AK Steel upgraded to Buy from Neutral at Longbow
12/20/17
12/20/17
UPGRADE
Target $7

Buy
AK Steel upgraded to Buy on positive survey results at Longbow
As previously reported, Longbow upgraded AK Steel to Buy from Neutral with a $7 price target. Analyst Chris Olin's latest carbon steel survey work suggests domestic producers are positioned to realize impressive earnings growth over the next 12-18 months on much higher flat rolled pricing, favorable automotive/annual contract rollovers, and pending tax reform. Olin raised his 2018 HRC price forecast by $45-$50/ton to $660-$670/ton and sees further upside should the DOC release a positive Section-232 recommendation in mid-January.
FDX FedEx
$265.92

1.04 (0.39%)

01/05/18
UBSW
01/05/18
UPGRADE
UBSW
Buy
FedEx upgraded to Buy from Neutral at UBS
01/05/18
UBSW
01/05/18
UPGRADE
Target $302
UBSW
Buy
FedEx upgraded to Buy on tax reform, favorable environment at UBS
As previously reported, UBS analyst Thomas Wadewitz upgraded FedEx to Buy from Neutral after factoring the Tax Cuts & Jobs Act into his forecasts. The analyst, who also cited signs that point toward a favorable volume and pricing environment for freight transports in 2018, set a $302 price target on FedEx shares.
01/05/18
01/05/18
UPGRADE
Target $164

Buy
Union Pacific upgraded to Buy at UBS
As previously reported, UBS analyst Thomas Wadewitz upgraded Union Pacific (UNP) to Buy from Neutral after factoring the Tax Cuts & Jobs Act into his forecasts. The analyst, who also cited signs that point toward a favorable volume and pricing environment for freight transports in 2018, also upgraded Werner (WERN) and FedEx (FDX) this morning. He set a $164 price target on Union Pacific shares.
01/08/18
DBAB
01/08/18
NO CHANGE
Target $145
DBAB
Buy
Deutsche names UPS a Top Pick, ups price target to $145
Deutsche Bank analyst Amit Mehrotra raised his price target for UPS (UPS) to $145 and $135 and elevated the shares to Top Pick status in Air Freight & Logistics, along with Knight-Swift (KNX), FedEx (FDX) and XPO Logistics (XPO). The analyst's earnings estimates for UPS have been revised 10% higher to reflect the passage of corporate tax reform. He also estimates that tax reform equates to about $1B of incremental free cash flow per annum. 5% cash tax rate. Mehrotra believes UPS shares are underappreciated and he maintains a Buy rating on the name.
STZ Constellation Brands, also tag STZ.B
$219.88

-5.91 (-2.62%)

01/05/18
EVER
01/05/18
NO CHANGE
EVER
Constellation Brands price target raised to $250 from $235 at Evercore ISI
Evercore ISI analyst Robert Ottenstein raised his price target on Constellation Brands to $250 from $235, citing in-line Q3 operating results, a favorable business and tax rate outlook, and the company's buyback authorization. Ottenstein has an Outperform rating on Constellation shares.
01/04/18
WELS
01/04/18
NO CHANGE
Target $260
WELS
Outperform
Constellation Brands price target raised to $260 from $235 at Wells Fargo
Wells Fargo analyst Bonnie Herzog raised her price target for Constellation Brands to $260 from $235, citing tax reform and stronger macros. The analyst reiterates an Outperform rating on the shares.
12/13/17
DBAB
12/13/17
INITIATION
Target $244
DBAB
Buy
Constellation Brands initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Steve Powers started Constellation Brands with a Buy rating and $244 price target. The analyst sees momentum in the company's core beer portfolio.
01/08/18
DBAB
01/08/18
NO CHANGE
Target $253
DBAB
Buy
Constellation Brands selloff creates 'compelling' setup, says Deutsche Bank
Deutsche Bank analyst Steve Powers believes Friday's post-earnings selloff in shares of Constellation Brands creates a "compelling" setup for Q4. The analyst attributes nearly all of the Q3 shortfall to timing, and sees underlying business trends as intact. Powers believes the relative Q3 shortfall creates a compelling Q4 set-up premised on Beer business reacceleration. He raised his price target for the shares to $253 from $248 and reiterates a Buy rating on Constellation.
KMI Kinder Morgan
$18.95

-0.06 (-0.32%)

10/17/17
GSCO
10/17/17
DOWNGRADE
Target $22
GSCO
Neutral
Kinder Morgan downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Theodore Durbin downgraded Kinder Morgan to Neutral citing a more balanced risk/reward profile following the realization of catalysts. The analyst also sees ongoing regulatory and execution risk. He cut his price target for the shares to $22 from $26.
01/04/18
FBCO
01/04/18
INITIATION
Target $23
FBCO
Outperform
Kinder Morgan initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kristina Kazarlan initiated Kinder Morgan with an Outperform rating and a price target of $23. The analyst says the valuation suggests the MLP may not need a direct catalyst, adding that "a quiet but well-executed 2018" justifies the rating.
08/30/17
MSCO
08/30/17
UPGRADE
MSCO
Overweight
Dominion Midstream, Hess Midstream Partners upgraded at Morgan Stanley
As previously reported, Morgan Stanley analyst Tom Abrams upgraded Dominion Midstream (DM) and Hess Midstream Partners (HESM), both to Overweight from Equal Weight, as he sees better value in the space after a few months of sector underperformance. He particularly likes equities expected to show higher growth in Distributable Cash Flow per unit, which includes Dominion Midstream and Hess Midstream Partners, he tells investors. Abrams also reiterated his Overweight ratings on Energy Transfer Equity (ETE), Kinder Morgan (KMI), Antero Midstream Partners (AM) and Phillips 66 Partners (PSXP), also citing their valuations relative to their cash flow.
10/19/17
RHCO
10/19/17
NO CHANGE
Target $23
RHCO
Buy
Kinder Morgan price target lowered to $23 from $26 at SunTrust
SunTrust analyst Tristan Richardson lowered his price target on Kinder Morgan to $23 to reflect the risk of delay on TransMountain project that has now been identified by the management. Richardson says the recent stock selloff was in anticipation of this delay, adding that investor focus may now shift to encouraging progress made on the Gulf Coast Express project. The analyst keeps his Buy rating on Kinder Morgan.
DB Deutsche Bank
$18.55

-1.22 (-6.17%)

11/14/17
HSBC
11/14/17
UPGRADE
HSBC
Buy
Deutsche Bank upgraded to Buy from Hold at HSBC
HSBC analyst Alevizos Alevizakos upgraded Deutsche Bank to Buy and raised his price target for the shares to EUR 18 from EUR 14. The current valuation seemingly ignores the upside inherent in the bank's improved capital position, Alevizakos tells investors in a research note. The analyst believes excess capital creates optionality for the Deutsche.
11/14/17
11/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Coca-Cola (KO) upgraded to Outperform from Market Perform at Wells Fargo with analyst Bonnie Herzog saying the shares should be a core holding in 2018 and beyond. 2. Deutsche Bank (DB) upgraded to Buy from Hold at HSBC with analyst Alevizos Alevizakos saying the current valuation seemingly ignores the upside inherent in the bank's improved capital position. 3. Famous Dave's (DAVE) upgraded to Buy from Hold at Craig-Hallum with analyst Alex Fuhrman citing the third quarter results beat, refranchising efforts progressing well and further G&A reductions targeted. 4. ADP (ADP) resumed at Equal Weight, up from Underweight, at Morgan Stanley with analyst Danyal Hussain saying he expects ADP to execute with a greater sense of urgency, but there is still "more work to do" and the proxy fight has put a spotlight on some concerns on which investors will remain focused, including margins and potential share losses, he tells investors. 5. Phoenix New Media (FENG) upgraded to Outperform from Neutral at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/20/17
11/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wal-Mart (WMT) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew Fassler sayign valuation following "powerful" share appreciation now reflects the company's progress in growing earnings. 2. Five Below (FIVE) downgraded to Hold from Buy at Loop Capital with analyst Anthony Chukumba citing valuation. 3. Live Nation (LYV) downgraded to In Line from Outperform at Evercore ISI with analyst David Joyce citing valuation. 4. Monster Beverage (MNST) downgraded to Negative from Neutral at Susquehanna with analyst Pablo Zuanic citing its high valuation, which he believes is misplaced due to assumptions about an offer from Coca-Cola (KO). 5. Deutsche Bank (DB) downgraded to Underperform from Market Perform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/20/17
KBWI
11/20/17
DOWNGRADE
KBWI
Underperform
Deutsche Bank downgraded to Underperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst George Karamanos downgraded Deutsche Bank to Underperform.
WMB Williams
$32.46

-0.09 (-0.28%)

05/08/17
05/08/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Varian Medical (VAR) upgraded to Buy from Neutral by Citi analyst Amit Hazan, who said the company is entering its strongest new product cycle period in at least seven years with Halcyon and HyperArc. BTIG analyst Sean Lavin also upgraded Varian Medical to Buy with a $106 price target following the "surprising" launch of its new Halcyon System. 2. Wells Fargo analyst Sharon Lui upgraded Williams Companies (WMB) to Outperform with an increased price target target range of $34-$36, telling investors that its strengthened financial profile and "attractive" long-term dividend growth profile should drive multiple expansion. 3. Goldman Sachs analyst James Schneider upgraded TSYS (TSS) to Buy, saying he sees "several" catalysts for the shares, including the May 24 analyst day and a return to earnings beats. 4. Buckingham analyst Kelly Halsor upgraded Restoration Hardware (RH) to Neutral from Underperform after the company completed its $300M stock buyback program and authorized an additional $700M of share buybacks. The analyst thinks that the fact that the company completed its $300M of buybacks without drawing on its revolver indicates that its inventory has been significantly lowered. 5. Evercore ISI analyst David Raso upgraded United Rentals (URI) to Outperform from In Line, citing valuation, and maintained his $134 price target on shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/17
LEHM
07/18/17
UPGRADE
LEHM
Overweight
Williams upgraded to Overweight from Equal Weight at Barclays
09/25/17
WOLF
09/25/17
INITIATION
Target $34
WOLF
Outperform
Williams initiated with an Outperform at Wolfe Research
Wolfe Research initiated Williams with an Outperform and a $34 price target.
01/04/18
FBCO
01/04/18
INITIATION
FBCO
Outperform
Williams initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kristina Kazarlan initiated Williams with an Outperform rating and a price target of $36, citing the company's natural gas strategy along the Eastern seaboard.

TODAY'S FREE FLY STORIES

FIT

Fitbit

$5.93

0.22 (3.86%)

15:00
08/20/18
08/20
15:00
08/20/18
15:00
Options
Fitbit calls active as shares extend gains »

Fitbit calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

MMM

3M

$204.54

-0.27 (-0.13%)

, SGMS

Scientific Games

$30.45

0.85 (2.87%)

14:53
08/20/18
08/20
14:53
08/20/18
14:53
Hot Stocks
3M announces filing of touch screen technology patent infringement lawsuit »

3M (MMM) and 3M…

MMM

3M

$204.54

-0.27 (-0.13%)

SGMS

Scientific Games

$30.45

0.85 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPY

Brookfield Property

$19.94

-0.15 (-0.75%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Conference/Events
Brookfield Property management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

LCI

Lannett

$5.40

-8.1 (-60.00%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Downgrade
Lannett rating change  »

Lannett downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

AABA

Altaba

$69.92

1.74 (2.55%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Options
Altaba Inc options imply 7.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$20.26

0.31 (1.55%)

14:47
08/20/18
08/20
14:47
08/20/18
14:47
Conference/Events
Summit Materials management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

  • 10

    Sep

CAPL

CrossAmerica

$18.15

0.15 (0.83%)

, ANDV

Andeavor

$147.76

2.82 (1.95%)

14:46
08/20/18
08/20
14:46
08/20/18
14:46
Hot Stocks
FTC approves Alimentation Couche-Tard sale of two Minnesota fuel stations »

The Federal Trade…

CAPL

CrossAmerica

$18.15

0.15 (0.83%)

ANDV

Andeavor

$147.76

2.82 (1.95%)

ANCUF

Alimentation Couche-Tard

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$15.94

0.61 (3.98%)

14:45
08/20/18
08/20
14:45
08/20/18
14:45
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHII

PHI, Inc

$8.59

0.09 (1.06%)

14:45
08/20/18
08/20
14:45
08/20/18
14:45
Hot Stocks
Alesia Value fund reports 4.7% stake in PHI »

On August 20,Alesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$216.05

-1.6 (-0.74%)

14:41
08/20/18
08/20
14:41
08/20/18
14:41
Periodicals
Breaking Periodicals news story on Apple »

Apple planning revamped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCHVF

MGM China

$0.00

(0.00%)

14:36
08/20/18
08/20
14:36
08/20/18
14:36
Upgrade
MGM China rating change  »

MGM China upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
08/20/18
08/20
14:35
08/20/18
14:35
General news
The Fed has become an unexpected focus »

The Fed has become an…

14:35
08/20/18
08/20
14:35
08/20/18
14:35
General news
Canada wholesale preview »

Canada wholesale preview:…

CTWS

Connecticut Water

$69.10

0.1 (0.14%)

14:34
08/20/18
08/20
14:34
08/20/18
14:34
Hot Stocks
PURA approves rate settlement agreement for Connecticut Water »

Connecticut Water Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMB

Williams

$30.38

-0.095 (-0.31%)

14:30
08/20/18
08/20
14:30
08/20/18
14:30
Conference/Events
Williams management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

AMZN

Amazon.com

$1,880.70

-1.24 (-0.07%)

14:29
08/20/18
08/20
14:29
08/20/18
14:29
Periodicals
Amazon hires well-known cardiologist amid push into health, CNBC says »

Amazon has hired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

AMCX

AMC Networks

$61.70

1.28 (2.12%)

14:25
08/20/18
08/20
14:25
08/20/18
14:25
Conference/Events
AMC Networks management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

OSPR

Osprey Energy Acquisition

$11.27

0.065 (0.58%)

14:25
08/20/18
08/20
14:25
08/20/18
14:25
Conference/Events
Osprey Energy Acquisition to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

PPG

PPG

$109.64

1.23 (1.13%)

14:24
08/20/18
08/20
14:24
08/20/18
14:24
Conference/Events
PPG management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

NFLX

Netflix

$330.55

13.77 (4.35%)

14:21
08/20/18
08/20
14:21
08/20/18
14:21
Technical Analysis
Technical Take: Netflix may test downtrend resistance line »

The shares are up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/20/18
08/20
14:17
08/20/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/20/18
08/20
14:16
08/20/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LCI

Lannett

$5.35

-8.15 (-60.37%)

14:16
08/20/18
08/20
14:16
08/20/18
14:16
Downgrade
Lannett rating change  »

Lannett downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

MBI

MBIA

$10.78

-0.22 (-2.00%)

14:15
08/20/18
08/20
14:15
08/20/18
14:15
Options
MBIA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$30.79

0.05 (0.16%)

14:08
08/20/18
08/20
14:08
08/20/18
14:08
Hot Stocks
SEC says Merrill Lynch to pay $8.9M to settle charges of undisclosed conflict »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.